Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years
Stockholm, Sweden: Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer ...
Sep 25, 2011
0
0